Sahajanand Medical Technologies

The RHP-cited Frost & Sullivan study forecasts 6.2% annual growth in the global medical-device market during 2025–2030. The cardiovascular-device market is forecast to grow 7.5% over the same period. Ageing populations and cardiovascular disease prevalence increase the addressable patient base, while affordability and procedure access constrain actual penetration.
The key drivers are:

• The global medical-device market growth projection is 6.2% CAGR for 2025–2030, from the RHP commissioned market study

• The cardiovascular-device market is projected to grow at 7.5% CAGR for 2025–2030, as reported in the RHP

• Global volumes depend on coronary interventions, structural-heart adoption, physician skill and clinical referral patterns, not merely disease prevalence

• Tender structures, reimbursements and imported-device pricing influence how healthcare activity translates into manufacturer revenue

Minimally invasive percutaneous coronary intervention can substitute for selected open procedures and creates demand for stents, PTCA balloons and catheters. Competition focuses on clinical outcomes, deliverability, drug coatings, regulatory submissions and physician acceptance, with increasing pricing pressure in mature markets.
The key drivers are:

• The RHP estimates the global drug-eluting stent market at USD 4.3 Bn in 2025 and USD 5.9 Bn by 2030

• India’s drug-eluting stent market is estimated at USD 205.1 Mn in 2025 and USD 307.2 Mn by 2030

• SMT’s FY26 VI-device contribution was 61.1% of operating revenue, making PCI demand and device economics central

• FY26 capacity utilisation was 78.3% for stents and 91.7% for catheters; growth may require yield management and selective capacity increases

Transcatheter aortic valve implantation (TAVI) provides a catheter-based option in aortic-valve disease, subject to patient eligibility, specialist centre availability and procedure economics. Occluder devices address selected structural defects. Both require training, evidence and specialised hospital relationships.

The key drivers are:

• SMT markets its Hydra self-expanding transcatheter heart valve and Cocoon occluders within the structural-heart category

• Structural-heart devices generated 16.8% of FY26 sales, rising from 12.3% in FY24, according to product mix KPIs

• Hydra TAVI manufacturing capacity reached 9,000 units in FY26, with 19.8% utilisation; commercial scale remains a separate question

• Device acceptance is tied to physician training, clinical data, registrations, reimbursements and reliable post-market surveillance

Implantable cardiac devices carry clinical, manufacturing and legal risks. Design defects, recalls, sterilisation failures, approval delays, adverse events and product-liability claims could harm operating results. Price controls, public tender terms, reimbursement changes and intense global competition affect realisable prices and margins.

The key risks are:

• Regulatory approval or renewal failure in a key export market may block shipments and require costly corrective action

• Device defects, recalls, adverse outcomes and product-liability litigation can harm patient trust and brand reputation

• India’s stent price controls and overseas reimbursement policy may restrict pricing despite improved product features

• Concentration in implantable devices means surveillance and manufacturing-quality discipline are critical to long-term demand

India’s medical-device policy framework emphasises domestic manufacturing, medical-device parks, innovation and R&D, with regulatory oversight by CDSCO. Government support can help the industry ecosystem; no company-specific PLI award, subsidy amount or benefit is assumed here unless expressly verified in the RHP.
The key policies are:

• National Medical Devices Policy 2023 targets a stronger domestic medtech ecosystem and more predictable policy coordination

• Medical-device parks and R&D initiatives may expand testing, infrastructure and local supplier access, subject to execution

• CDSCO regulation and international approvals impose compliance costs alongside potential market-access benefits

• Price caps, procurement schemes and public reimbursement can increase volumes while reducing per-device margins